Every Booth Records Activity. Captello Proves Revenue.
The Next Generation of Captello Is Here: Bringing lead capture, meetings, activations, and event revenue intelligence in The Only Event-to-Revenue Intelligence Platform.... Read more.
Evogene Schedules Second Quarter 2026 Financial Results Release
Zoom conference call scheduled for August 18, 2026, 9:00 AM ET REHOVOT, Israel, July 30, 2026 /PRNewswire/ — Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering... Read more.
Lightspeed Announces First Quarter 2027 Financial Results
First quarter revenue of $322.7 million and organic1 revenue growth of 17%, exceeded outlook Gross profit of $138.6 million and organic1 gross profit growth of... Read more.
LUCY x TheBurntPeanut. Official.
Partnership embeds LUCY directly into the Peanut-verse, the fully custom 3D universe built around TheBurntPeanut’s character LAS VEGAS, July 30, 2026 /PRNewswire/... Read more.
TriNet Announces Second Quarter 2026 Results & Raises FY26 Earnings Guidance
50% Growth in GAAP Earnings per Diluted Share to $1.15 for the Second Quarter 2026 35% Growth in Adjusted Net Income per Diluted Share to $1.55 for the Second Quarter... Read more.
Webull Adds Benzinga’s Premium Newsfeed, Press Releases and Economic Calendar
Real-time equities news, press releases and economic data now power Webull’s trading platform DETROIT, July 30, 2026 /PRNewswire/ — Benzinga, a leading... Read more.
Daqo New Energy Issues Its 2025 Environmental, Social and Governance (ESG) Report
SHANGHAI, July 30, 2026 /PRNewswire/ — Daqo New Energy Corp. (NYSE: DQ) (“Daqo New Energy,” the “Company” or “we”), a... Read more.
Announcing Trimble Dimensions 2026 User Conference and Offsite Expo
Annual conference returns to Las Vegas to solve customer challenges, accelerate AI innovation and redefine the future of work across AEC and geospatial industries... Read more.
CREATE Medicines Receives Approval to Initiate First-in-Human Phase 1/2 Clinical Trial of In Vivo CAR-T Candidate CRT-402 for Autoimmune Diseases
Australian HREC approval clears the initiation of CREATE’s first-in-human Phase 1/2 study evaluating CRT-402 in patients with systemic lupus erythematosus... Read more.
Canadian Solar Schedules Second Quarter 2026 Earnings Conference Call for August 27
KITCHENER, ON, July 30, 2026 /PRNewswire/ — Canadian Solar Inc. (“the Company”, “Canadian Solar”) (NASDAQ: CSIQ) today announced that... Read more.